Michael Brennan to Immunosuppressive Agents
This is a "connection" page, showing publications Michael Brennan has written about Immunosuppressive Agents.
Connection Strength
0.710
-
Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin North Am. 2013 Oct; 57(4):631-55.
Score: 0.402
-
Pillemer SR, Leakan RA, Sankar V, Manny J, Baum BJ, Smith J, Chaudhry U, Fox PC, Radfar L, Ligier S, Brennan MT. Prominent adverse effects of thalidomide in primary Sjögren's syndrome. Arthritis Rheum. 2004 Jun 15; 51(3):505-6.
Score: 0.211
-
Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004 Jul; 50(7):2240-5.
Score: 0.053
-
Brennan MT, Sankar V, Baccaglini L, Pillemer SR, Kingman A, Nunez O, Young NS, Atkinson JC. Oral manifestations in patients with aplastic anemia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Nov; 92(5):503-8.
Score: 0.044